Tranexamic acid for bleeding. Much more than a treatment for post-partum haemorrhage.

Ian Roberts MD, PhD Professor, Miss Amy Brenner MSc, Haleema Shakur-Still MSc Professor

PII: S2589-9333(22)00154-9
DOI: https://doi.org/10.1016/j.ajogmf.2022.100722
Reference: AJOGMF 100722

To appear in: American Journal of Obstetrics & Gynecology MFM

Received date: 24 May 2022
Revised date: 1 August 2022
Accepted date: 13 August 2022

Please cite this article as: Ian Roberts MD, PhD Professor, Miss Amy Brenner MSc, Haleema Shakur-Still MSc Professor, Tranexamic acid for bleeding. Much more than a treatment for post-partum haemorrhage., American Journal of Obstetrics & Gynecology MFM (2022), doi: https://doi.org/10.1016/j.ajogmf.2022.100722

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Inc.
Tranexamic acid for bleeding. Much more than a treatment for post-partum haemorrhage.  
Professor Ian Roberts, MD, PhD, Miss Amy Brenner, MSc, Professor Haleema Shakur-Still, 
MSc, 

1Department of Population Health, London School of Hygiene and Tropical Medicine, 
Ian.Roberts@lshtm.ac.uk* 

2Department of Population Health, London School of Hygiene and Tropical Medicine, 
Amy.Brenner@lshtm.ac.uk 

3Department of Population Health, London School of Hygiene and Tropical Medicine, 
Haleema.Shakur-still@lshtm.ac.uk 

*Corresponding author: Room 814, London School of Hygiene & Tropical Medicine, Keppel 
Street, London WC1E 7HT 
Tel 020 7299 8128

Abstract

The evidence that early tranexamic acid treatment reduces post-partum haemorrhage 
Deaths has major implications for obstetric care world-wide. Tranexamic acid may also have 
a role in the prevention of post-partum haemorrhage but more evidence is needed on the 
Balance of risks and benefits. Most deaths from post-partum haemorrhage are in low- and 
middle-income countries where tranexamic acid treatment is often unavailable. Several 
Maternal health organisations including the Reproductive Health Supplies Consortium, 
Clinton Health Access Initiative, Concept Foundation, FIGO and UNITAID are working to 
increase access. However, a wider view of the evidence on tranexamic acid and bleeding 
shows that it can improve maternal health in many other ways. An appreciation of these 
Wider health benefits could facilitate efforts to increase access. By reducing heavy menstrual 
bleeding tranexamic acid could reduce the prevalence of maternal anaemia, a common 
and important risk factor for post-partum haemorrhage and other maternal and neonatal 
outcomes. Further clinical trials of tranexamic acid for the treatment of menstrual bleeding 
are needed. By reducing surgical bleeding and the need for blood transfusion, tranexamic
acid would increase the availability of blood in countries where there is a blood shortage so that more blood is available for use in life threatening bleeding including post-partum haemorrhage. In countries where there is no blood shortage, tranexamic acid use would reduce healthcare costs and prevent transfusion transmitted infections and reactions. Trauma affects women and men and violence is a leading cause of death in pregnancy. Increased use of tranexamic acid in trauma would significantly reduce trauma deaths. Efforts to increase the availability and use of tranexamic acid for obstetric haemorrhage should acknowledge its wider health benefits and aim to increase its use across health services more generally.

**Tranexamic acid for the treatment of post-partum haemorrhage.**

In 2017, the Woman trial showed that early treatment (within 3 hours of birth) with the antifibrinolytic drug tranexamic acid reduces post-partum haemorrhage deaths and the need for surgical intervention to control bleeding, without any increased risk of vascular occlusive events.\(^1\) Within months, tranexamic acid was included in WHO guidelines for the treatment of PPH.\(^2\) Based on the dosing regimen used in the Woman trial, the WHO recommended the intravenous (IV) administration of 1 gram of tranexamic acid with a second dose of 1 g IV if bleeding continues after 30 minutes, or if bleeding re-starts within 24 hours. Tranexamic acid is inexpensive, heat stable and has a long shelf life. A major advantage of tranexamic acid is that it reduces PPH deaths regardless of the cause of the bleeding. A subgroup analysis of the Woman trial data found no evidence of heterogeneity in the effect of TXA on deaths due to bleeding according to the cause of the bleeding. When interpreting the results of subgroup analyses, the best working assumption is that the overall result probably applies to everyone unless there is good evidence to the contrary. In this case, the effect of TXA on death due to bleeding was slightly different in the atony and non-atony groups, but the heterogeneity p value (p=0.36) showed that this difference is easily compatible with the play of chance. The Woman trial showed that tranexamic acid significantly reduces bleeding deaths and the need for laparotomy to control bleeding even when the primary cause of bleeding was uterine atony. This stands in contrast with uterotonic drugs which should only affect PPH resulting from uterine atony, which is variably estimated at 60-70% of PPH cases.

There is strong evidence that tranexamic acid is most effective when given as soon as possible after bleeding onset and the WHO recommended that tranexamic acid should be given immediately after PPH diagnosis, along with uterotonic drugs. On the other hand, the American College of Obstetricians and Gynaecologists (ACOG) recommended that tranexamic acid should be administered when initial therapies fail.\(^3\) Waiting to see if initial therapies fail is likely to lead to delayed administration and will reduce the benefits of tranexamic acid treatment. Whatever the cause of the bleeding, waiting to see if uterotonic fail, can only lead to delayed tranexamic acid treatment, placing mothers at increased risk of consumptive coagulopathy.

Despite the lifesaving benefits of tranexamic acid as a treatment of PPH, in many low- and middle-income countries, where most deaths from PPH occur, tranexamic acid is often unavailable. Efforts to scale-up global access to tranexamic acid for PPH treatment are underway. The Reproductive Health Supplies Coalition, Clinton Health Access Initiative,
Concept Foundation, FIGO, E-MOTIVE trial and other organizations are working to bring tranexamic acid treatment to all women with PPH. As with any new drug, the barriers to scale up are bottlenecks in country procurement and distribution, with limited supply forcing up prices. However, it is not widely appreciated that tranexamic acid can improve maternal health in many other ways apart from the treatment of PPH and a more ‘health systems-oriented’ approach to its availability and use could have additional health benefits. Because market forces determine the availability and cost of tranexamic acid in many countries, appreciation of its wider health benefits could have strategic advantages since the potential demand for TXA is much more than as a PPH treatment. This potential demand could become effective demand if there was an appreciation of its other benefits within the health system. So what other health benefits could tranexamic acid have apart from as a treatment for PPH?

**Tranexamic acid for the prevention of post-partum haemorrhage.**

The knowledge that tranexamic treatment of post-partum haemorrhage improves outcomes has raised interest in the use of tranexamic acid for the prevention of severe bleeding. All women bleed after childbirth. As if anticipating this inevitability, the mother’s blood becomes progressively prothrombotic in pregnancy. Levels of clot-making proteins like fibrinogen and factor VII increase, while the activity of clot breaking (fibrinolytic) proteins is reduced due to higher levels of inhibitors. The placenta itself releases potent inhibitors of fibrinolysis (PAI-1 and PAI-2). Their blood levels peak at the moment of birth, falling away rapidly after placental separation. Given the strong evolutionary links between coagulation and immunity, protection from pathogens might have been one of the selection pressures moulding the haemostatic system. Whatever the biological purpose, there are profound changes in the mother’s blood around the time of birth.

Despite the prothrombotic tendency, bleeding after childbirth can be severe and sometimes fatal. In parts of sub-Saharan Africa and South Asia, one mother dies from bleeding for every 1,000 births. In high-income countries, the risk is orders of magnitude lower, with less than 1 bleeding death per 100,000 births. In these low risk settings, there are more thrombotic deaths than bleeding deaths. Due to propensity of the blood to clot and the pressure from the expanding womb, pregnant women have an increased risk of arterial and venous thrombosis. Compared to women who are not pregnant, the risk of thromboembolism in pregnancy is five times higher, rising to 20 times higher in the post-partum period. To complicate matters, women giving birth are not exposed to one risk (bleeding) or the other (thrombosis) but to both risks simultaneously. Severe bleeding is a risk factor for thrombosis. For this reason, before deciding to use a treatment to prevent bleeding, we must consider the risk of bleeding and thrombosis and the effect of the treatment on both.

The Woman trial evaluated the effects of TXA in mothers with severe bleeding after childbirth. All of the included women were bleeding profusely and most were haemodynamically unstable. Their risk of death from bleeding was extremely high, about 20 deaths per 1,000 births. Their risk of death from thrombosis was also high at 1 death per 1,000 births but much less than the risk of death from bleeding. TXA cut bleeding deaths by a third when given within three hours of birth, preventing about 6 deaths for every 1,000 women treated. There was no apparent effect of TXA on thrombosis deaths but because
there were only 21 thrombotic deaths in this 20,060-patient trial there is uncertainty about the effects of TXA on this outcome. Nevertheless, this uncertainty does not materially affect the treatment decision. Even if TXA doubled the risk of thrombotic deaths, which seems highly unlikely, in women with severe bleeding the benefit would outweigh the harms. As recommended by the World Health Organization, all women with severe post-partum bleeding should receive TXA.²

But does TXA improve outcomes for women without severe bleeding? The Woman-2 trial is evaluating the effects of TXA after childbirth in women with moderate or severe anaemia.⁸ In this trial, anaemic women are treated immediately after birth, as soon as the umbilical cord is clamped. Anaemia is a strong risk factor for bleeding after childbirth.⁹ The increased heart rate and cardiac output caused by anaemia and the reduced viscosity of anaemic blood increase blood flow from bleeding vessels.¹⁰⁻¹² Red cells also appear to have a clot-stabilizing effect and anaemic clots are more susceptible to fibrinolysis.¹³ Women with severe anaemia have elevated D-dimer levels and lower platelet and fibrinogen levels.¹⁴ The risk of death from bleeding in these anaemic women is about 1 per 1,000 births and much higher than the risk of thrombotic death. Because anaemia increases the risk of bleeding and decreases the risk of thrombosis, the net effect of TXA should be favourable in anaemic women.

There have also been trials of TXA for PPH prevention in low risk women in high income countries.¹⁵⁻¹⁷ Because the risk of death from bleeding is low (about 1 per 100,000 deliveries) and similar to the risk of death from thrombosis, uncertainty about the effect of TXA on thrombosis is far more consequential. If there was an increase in thrombotic events with TXA this could outweigh the benefits of reduced bleeding. It is critical therefore that trials in low risk women are large enough to assess the effect of TXA on thrombosis. Because fatal events are so rare, we will need to study the effects of TXA on non-fatal thrombosis. But even then, we would only expect about 2 thrombotic events per 1000 births. Trials with just a few thousand low risk women will be underpowered and almost non-informative. Even the largest trial, which included 11,000 low risk women giving birth by Caesarean section, is too small to provide reliable information about safety. We will need larger trials and meta-analyses of these large trials before we can confidently offer TXA treatment to low risk women.

Are we being overcautious? Could a single injection of TXA to inhibit fibrinolysis for just a few hours, when the risk of bleeding is greatest, cause a significant increase in the risk of thrombosis? TXA has a short half-life and is almost completely eliminated within 6-8 hours. Severe bleeding that requires transfusion or surgery is itself prothrombotic and so by preventing bleeding we might even reduce the risk of thrombosis. Without reliable evidence we can only speculate but with over 140 million births each year world-wide, it would be rash to speculate about something so important.

**Tranexamic acid and heavy menstrual bleeding**

Anaemia is common and dangerous in women of reproductive age. Worldwide, half a billion women of reproductive age (1 in 3) have anaemia, with a particularly high burden in sub-Saharan Africa and South Asia.¹⁸⁻²⁰ Anaemia reduces capacity to benefit from education, to
work, and to participate in social and leisure activities. Because it affects educational attainment and work productivity, anaemia impacts national development. In pregnancy, it increases the risk of low birthweight, preterm birth, and perinatal, neonatal and maternal mortality. 

Menstruation is a major cause of anaemia in women of reproductive age and affects quality of life. Higher menstrual blood loss (40ml on average) is correlated with greater losses of iron (1.6mg on average) and Hb. The presence of anaemia strongly suggests that dietary intake of iron, B12 and folate is insufficient to compensate for menstrual losses of iron. As well as contributing to anaemia, menstrual symptoms like heavy menstrual bleeding affect women’s ability to undertake physical, social and academic activities which greatly impacts quality of life.

New strategies are needed to improve women’s health and achieve global anaemia targets. The WHO aims to halve anaemia prevalence in women of reproductive age by 2025. The prevalence of anaemia is falling, but slowly. From 1995-2011, global mean Hb increased by just 1g/L. Interventions to reduce menstrual bleeding have been neglected in anaemia control strategies, which largely focus on increasing the dietary intake of iron, B12 and folate but have had limited success.

By reducing menstrual iron loss, tranexamic acid has the potential to reduce anaemia regardless of whether it is caused by iron deficiency, underlying diseases, infections or genetic haemoglobinopathies. Endometrial fibrinolysis in normal menstruation provides the biological basis for using TXA to reduce menstrual losses of iron and Hb in anaemic women. Although the evidence that tranexamic acid reduces heavy menstrual bleeding is promising, further high-quality trials are needed in low- and middle-income settings. Such trials could change anaemia control policy globally, improve the wellbeing of millions of women, and help achieve the WHO target. Early intervention to reduce the risk of anaemia during pregnancy offers the potential to reduce adverse maternal and birth outcomes and to improve maternal wellbeing.

**Tranexamic acid and surgical bleeding**

Evidence that tranexamic acid reduces surgical bleeding and the need for blood transfusion has been available for decades but uncertainty about the risk of vascular occlusive events has limited its widespread use. Recent systematic reviews and meta-analyses of clinical trials of tranexamic acid in elective surgery show no increased risk of vascular occlusive events with tranexamic acid but because many of the included trials were small there was still some doubt about the balance of risks and benefits. However, the recent publication of the POISE-3 trial results is a substantive addition to our knowledge of the effects of tranexamic acid in surgery and warrants urgent attention. The POISE-3 trial randomly allocated close to 10,000 patients undergoing non-cardiac surgery to get tranexamic acid or placebo and showed that tranexamic acid reduced major bleeding by one quarter, significantly reduced blood transfusion and without increasing the risk of vascular occlusive events. For statistical reasons it is hard to rule out a very small increase in the risk of vascular occlusive events but because significant bleeding is surprisingly common
surgery and vascular occlusive events are relatively rare, the balance of benefits and risks will be favourable. As demonstrated previously, the POISE-3 trial showed that tranexamic acid reduces bleeding in all types of surgery, including gynaecological surgery. In high, middle- and low-income settings, the greater use of tranexamic acid in people having in-patient surgery would reduce surgical blood loss, post-operative anaemia and risks of transfusion transmitted infection. Economic evaluation shows that TXA is a highly cost-effective intervention for reducing the cost and risks associated with surgical procedures requiring blood transfusions in low- and middle-income settings, particularly in sub-Saharan Africa. By increasing the availability of blood, tranexamic acid could be lifesaving in those countries where there is a severe blood shortage. In most low-income countries there is a severely limited supply of safe blood for transfusion. The severe blood shortage is likely to explain the high frequency of single unit blood transfusions in women with severe postpartum bleeding, despite the need for higher volume transfusions. Use of tranexamic acid would also reduce health care costs and prevent transfusion transmitted infections including HIV, Hepatitis B and Hepatitis C in countries where blood is readily available. Given the recent outbreaks of new viral infections (Monkeypox and adenovirus causing hepatitis), avoiding unnecessary blood transfusion, whilst improving surgical outcomes, should have a high public health profile.

Tranexamic acid and traumatic bleeding

In 2010, results from the global CRASH-2 trial (20,211 polytrauma patients) showed that intravenous tranexamic acid given within 3 hours of injury reduces deaths due to bleeding and all-cause mortality. Based on these results tranexamic acid was added to the WHO list of essential medicines. In 2019, results from the global CRASH-3 trial (13,000 patients with isolated traumatic brain injury) showed that tranexamic acid given within 3 hours of injury also reduces head injury deaths, almost certainly by reducing the extent of traumatic intracranial bleeding. Early tranexamic acid treatment reduces trauma deaths regardless of country income, although misguided concerns about the generalisability of the trial results have limited the mortality benefits in some settings. The implications for women of the lifesaving benefits of tranexamic acid in trauma patients become obvious when one considers that violence is the leading cause of death during pregnancy and the postpartum period in the United States. A recent analysis of mortality data from the US National Center for Health Statistics showed that violence during pregnancy or within 42 days of the end of pregnancy exceeded all the leading causes of maternal mortality by more than twofold. The pregnancy associated homicide risk was particularly high in Black women and girls. Unfortunately, there is recent evidence that injured women are much less likely than men to receive tranexamic acid treatment. Advocates for women should ensure that when women are victims of injury or violence, they receive evidence-based trauma care including the use of tranexamic acid.

Table: Established indications for tranexamic acid

| Condition          | Dosing                                                                 |
|--------------------|----------------------------------------------------------------------|
| PPH                | 1-gram tranexamic acid as soon as possible after PPH onset (but no later than 3 hours from birth) reduces PPH deaths by a third and reduces the need for laparotomy for bleeding. |
Surgery: 1-gram tranexamic acid just prior to incision reduces surgical bleeding and the need for blood transfusion by between one quarter and one third.

Trauma: 1-gram tranexamic acid as soon as possible after injury (but no later than 3 hours) reduces deaths from bleeding by about one third.

Future research priorities

Timely treatment with intravenous (IV) tranexamic acid (TXA) cuts PPH deaths by one third. To increase access in LMICs, WHO has made finding different ways to give TXA a research priority. Women die soon after PPH and so effective TXA levels must be achieved quickly. Many community health workers cannot give IV drugs but most are trained to give IM injections (e.g. vaccination). Further research is needed on IM tranexamic acid use since this has the potential to take this lifesaving drug out of hospital into the community so that more women can be treated and sooner. We will also need larger trials and meta-analyses of large trials before we can offer TXA for the prevention of PPH in low risk women. Clinical trials of the role of tranexamic acid in the treatment of heavy menstrual bleeding and the prevention of anaemia are also needed.

Conclusions

The inclusion of tranexamic acid into WHO guidelines on the treatment of post-partum haemorrhage has led to a profusion of initiatives to increase the availability and use of tranexamic acid for this specific indication. However, tranexamic acid can improve maternal health in many other ways and a more ‘health systems-oriented’ approach to tranexamic acid availability and use would have major additional health benefits. Tranexamic acid is a key component of the PPH treatment bundle and the Reproductive Health Supplies Consortium, CHAI, Concept Foundation, FIGO and other organizations are working to scale up access to tranexamic acid in low- and middle-income countries. Recognising the wider health system uses and benefits of tranexamic acid use has the potential to expand the hospital demand for tranexamic acid which should lead to increased supply. A health systems approach to tranexamic acid availability and use would have enormous benefits. Anaemia due to heavy menstrual bleeding debilitates millions of young women, reducing their ability to develop to their full potential. Access to tranexamic acid could be life changing for these women. By reducing surgical bleeding tranexamic acid could increase the blood supply for women who need it. Injury and violence kill 5 million men and women each year and wider use of tranexamic acid could save over one hundred thousand deaths each year. Tranexamic acid is an essential medicine for surgical, traumatic and post-partum bleeding and must be available in hospitals everywhere.

References

1 WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 389: 2105–16.
2 World Health Organization. Updated WHO Recommendation on Tranexamic Acid for the Treatment of Postpartum Haemorrhage. 2017; : 1–5.
3 ACOG Expands Recommendations to Treat Postpartum Hemorrhage | ACOG. https://www.acog.org/news/news-releases/2017/09/acog-expands-recommendations-to-treat-postpartum-hemorrhage (accessed May 24, 2022).
4 Hellgren M. Hemostasis during normal pregnancy and puerperium. *Semin Thromb Hemost* 2003; **29**: 125–30.
5 Kruithof EK, Tran-Thang C, Gudinchet A, *et al.* Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. *Blood* 1987; **69**: 460–6.
6 Knight M, Bunch K, Tuffnell D, *et al.* Saving Lives, Improving Mothers’ Care Maternal, Newborn and Infant Clinical Outcome Review Programme. 2021. www.hqip.org.uk/national-programmes. (accessed May 24, 2022).
7 James AH. Venous thromboembolism in pregnancy. *Arterioscler Thromb Vasc Biol* 2009; **29**: 326–31.
8 Ker K, Roberts I, Chaudhri R, *et al.* Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: study protocol for an international, randomised, double-blind, placebo-controlled trial. *Trials* 2018; **19**: 712.
9 Nair M, Choudhury MK, Choudhury SS, *et al.* Association between maternal anaemia and pregnancy outcomes: A cohort study in Assam, India. *BMJ Glob Heal* 2016; **1**: e000026.
10 Weiskopf RB, Viele MK, Feiner J, *et al.* Human cardiovascular and metabolic response to acute, severe isovolemic anemia. *JAMA* 1998; **279**: 217–21.
11 Whittaker SRF, Winton FR. The apparent viscosity of blood flowing in the isolated hindlimb of the dog, and its variation with corpuscular concentration. *J Physiol* 1933; **78**: 339–69.
12 Guyton AC, Richardson TQ. Effect of hematocrit on venous return. *Circ Res* 1961; **9**: 157–64.
13 Wohner N, Sótonyi P, MacHovich R, *et al.* Lytic resistance of fibrin containing red blood cells. *Arterioscler Thromb Vasc Biol* 2011; **31**: 2306–13.
14 Nair M, Chhabra S, Choudhury SS, *et al.* Relationship between anaemia, coagulation parameters during pregnancy and postpartum haemorrhage at childbirth: a prospective cohort study. 2021; **11**: e050815.
15 Sentilhes L, Winer N, Azria E, *et al.* Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery. *N Engl J Med* 2018; **379**: 731–42.
16 Sentilhes L, Sénat M V., Le Lous M, *et al.* Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery. *N Engl J Med* 2021; **384**: 1623–34.
17 Pacheco LD. Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial. *Am J Obstet Gynecol* 2022; **226**: S779–80.
18 Young MF. Maternal anaemia and risk of mortality: a call for action. *Lancet Glob. Heal.* 2018; **6**: e479–80.
19 Sunuwar DR, Singh DR, Chaudhary NK, Pradhan PMS, Rai P, Tiwari K. Prevalence and factors associated with anemia among women of reproductive age in seven South and Southeast Asian countries: Evidence from nationally representative surveys. *PLoS One* 2020; **15**: e0236449.
20 Stevens GA, Finucane MM, De-Regil LM, *et al.* Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995–2011: A systematic analysis of population-representative data. *Lancet Glob Heal* 2013; **1**: e16–25.
Haas JD, Brownlie IV T. Iron deficiency and reduced work capacity: A critical review of the research to determine a causal relationship. In: Journal of Nutrition. American Institute of Nutrition, 2001. DOI:10.1093/jn/131.2.676s.

Rahman MM, Abe SK, Rahman MS, et al. Maternal anemia and risk of adverse birth and health outcomes in low- and middle-income countries: Systematic review and meta-analysis. Am J Clin Nutr 2016; 103: 495–504.

Young MF, Oaks BM, Tandon S, Martorell R, Dewey KG, Wendt AS. Maternal hemoglobin concentrations across pregnancy and maternal and child health: a systematic review and meta-analysis. Ann. N. Y. Acad. Sci. 2019; 1450: 47.

Daru MBBS J, Zamora J, Thangaratinam S, et al. Risk of maternal mortality in women with severe anaemia during pregnancy and post partum: a multilevel analysis. Lancet Glob Heal 2018; 6: e548–54.

Ofojekwu M-JN, Nnanna OU, Okolie CE, Odewumi LA, Isiguzoro IOU, Lugos MD. Hemoglobin and Serum Iron Concentrations in Menstruating Nulliparous Women in Jos, Nigeria. Lab Med 2013; 44: 121–4.

Barr F, Brabin L, Agbaje S, Buseri F, Ikimalo J, Briggs N. Reducing iron deficiency anaemia due to heavy menstrual blood loss in Nigerian rural adolescents. Public Health Nutr 1998; 1: 249–57.

Hallberg L, Högdahl A - M, Nilsson L, Rybo G. Menstrual Blood Loss and Iron Deficiency. Acta Med Scand 1966; 180: 639–50.

Schoep ME, Nieboer TE, van der Zanden M, Braat DDM, Nap AW. The impact of menstrual symptoms on everyday life: a survey among 42,879 women. Am J Obstet Gynecol 2019; 220: 569.e1-569.e7.

WHO. Global anaemia reduction efforts among women of reproductive age: impact, achievement of targets and the way forward for optimizing efforts. 2020 https://www.who.int/publications/i/item/9789240012202 (accessed Jan 18, 2021).

Critchley HOD, Munro MG, Shakur-Still H, Roberts I. Menstruation should not be overlooked in control of anaemia. Lancet. 2021; 397: 26.

Gleeson N c., Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994; 73: 274–7.

Bryant-Smith AC, Lethaby A, Farquhar C, Hickey M. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst. Rev. 2018; 2018. DOI:10.1002/14651858.CD000249.pub2.

Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012; 344: e3054.

Ker K, Prieto-Merino D, Roberts I. Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss. Br. J. Surg. 2013. DOI:10.1002/bjs.9193.

Taeuber I, Weibel S, Herrmann E, et al. Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality: A Systematic Review, Meta-analysis, and Meta-regression. JAMA Surg 2021; 156: e210884–e210884.

Murao S, Nakata H, Roberts I, Yamakawa K. Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis. Crit Care 2021; 25: 1–11.

Devereaux PJ, Marcucci M, Painter TW, et al. Tranexamic Acid in Patients Undergoing Noncardiac Surgery. N Engl J Med 2022; published online April 2.
Guerriero C, Cairns J, Jayaraman S, Roberts I, Perel P, Shakur H. Giving tranexamic acid to reduce surgical bleeding in sub-Saharan Africa: an economic evaluation. *Cost Eff Resour Alloc* 2010 81 2010; 8: 1–11.

CRASH-2 trial collaborators, Shakur H, Roberts I, *et al.* Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. *Lancet (London, England)* 2010; 376: 23–32.

CRASH-3 Collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. *Lancet* 2019; 394: 1713–23.

Roberts I, Shakur-Still H. Tranexamic acid for trauma in the USA: is prejudice a barrier to saving lives? *Lancet* 2022; 399: 1675–7.

Wallace M, Gillispie-Bell V, Cruz K, Davis K, Vilda D. Homicide During Pregnancy and the Postpartum Period in the United States, 2018-2019. *Obstet Gynecol* 2021; 138: 762–9.

Nutbeam T, Roberts I, Weekes L, Shakur-Still H, Brenner A, Ageron F-X. Use of tranexamic acid in major trauma: a sex-disaggregated analysis of the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2 and CRASH-3) trials and UK trauma registry (Trauma and Audit Research Network) data. *Br J Anaesth* 2022; published online May. DOI:10.1016/J.BJA.2022.03.032.

Ker K, Kiriya J, Perel P, Edwards P, Shakur H, Roberts I. Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial. *BMC Emerg Med.* 2012;12:3. Epub 2012/03/03.